Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma

NCT06500273 is registered in ClinicalTrials.gov with Allogene Therapeutics as lead sponsor.

NCT NCT06500273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06500273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
Lead sponsor
Allogene Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 18, 2024
Completion date
December 31, 2032
Enrollment
250 (estimated)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma